Zorawar S Noor, Amy L Cummings, McKenna M Johnson, Marshall L Spiegel, Jonathan W Goldman
Lung cancer is a heterogeneous disease, and the availability of comprehensive genomic profiling has allowed for the characterization of its molecular subtypes. This has increased the ability to deliver "personalized medicines" by tailoring therapies to target driver mutations in a patient's cancer. The development of targeted therapies for non-small cell lung cancer (NSCLC) has helped define the era of precision medicine throughout oncology. This article aims to contextualize recent research and provide an updated summary of targeted therapies available for patients with NSCLC...
June 2020: Seminars in Respiratory and Critical Care Medicine
Min Su, Dehui Huang, Liuqing Sun, Zhao Dong, Lei Wu, Shengyuan Yu
Background : Being a subtype of primary central nervous system lymphoma (PCNSL), primary vitreoretinal lymphoma (PVRL) is a rare and fatal intraocular malignancy manifesting as blurred vision and floaters, and is usually combined with, or eventually progresses to, central nervous system lesions. The diagnosis of PVRL/PCNSL remains challenging because of the nonspecific clinical features and diagnostic dependency on biopsy. Case presentation : In this paper, we present the clinical, imaging, laboratory, brain biopsy, and vitreous biopsy findings of a 56-year-old immunocompetent woman who presented with blurred vision of the left eye, but which rapidly evolved into lesions of the central nervous system...
May 25, 2020: International Journal of Neuroscience
Shu-Nan Qi, Yong Yang, Yu-Jing Zhang, Hui-Qiang Huang, Ying Wang, Xia He, Li-Ling Zhang, Gang Wu, Bao-Lin Qu, Li-Ting Qian, Xiao-Rong Hou, Fu-Quan Zhang, Xue-Ying Qiao, Hua Wang, Gao-Feng Li, Yuan Zhu, Jian-Zhong Cao, Jun-Xin Wu, Tao Wu, Su-Yu Zhu, Mei Shi, Li-Ming Xu, Zhi-Yong Yuan, Hang Su, Yu-Qin Song, Jun Zhu, Chen Hu, Ye-Xiong Li
We aimed to determine the survival benefits of chemotherapy (CT) additional to radiotherapy (RT) in different risk groups of patients with early-stage extranodal nasal-type NK/T-cell lymphoma (ENKTCL) and to investigate the risk of postponing RT based on induction CT responses. A total of 1360 patients who received RT with or without new-regimen CT from 20 institutions were retrospectively reviewed. The patients had received RT alone, RT followed by CT (RT+CT), or CT followed by RT (CT+RT). The patients were stratified into different risk groups using the nomogram-revised risk index (NRI)...
May 25, 2020: American Journal of Hematology
Anna Asklid, Sandra Eketorp Sylvan, Agnes Mattsson, Maria Winqvist, Hemming Johansson, Anders Österborg, Lotta Hansson
This real-world study investigated outcome of first-line treatment in elderly patients with diffuse large B-cell lymphoma (DLBCL). All ( n  = 292) new DLBCL patients ≥80 years diagnosed in the Stockholm region from 2000-2015 were included. Median age was 85 years, most had good performance status and low comorbidity score. CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone) was used in 60/230 patients, R-CHOP in 170/230. Only 12% of patients aged 80-84 years and 6% of ≥85 years received full-dose chemotherapy...
May 25, 2020: Leukemia & Lymphoma
Cristian Aguilar, Caddie Laberiano, Brady Beltran, Cecilia Diaz, Alvaro Taype-Rondan, Jorge J Castillo
Primary effusion lymphoma (PEL) is an aggressive B-cell lymphoma confined to body cavities and universally associated with human herpesvirus type 8 infection. The prognosis of this entity remains poor, with a median survival time of 6 to 9 months. To better understand the clinicopathologic features of the disease and identify possible prognostic factors, we performed a systematic review of the literature for cases of PEL, including 2 previously unreported cases from our institution. PEL was more prevalent in men (92%), with a median age at diagnosis of 55 years...
May 25, 2020: Leukemia & Lymphoma
Takashi Yamazaki, Lizhi Liu, Erin G Colon, James L Manley
Burkitt lymphoma (BL) is an aggressive B-cell lymphoma characterized by translocation and deregulation of the proto-oncogene c-MYC.Transcription factor 3(TCF3) has also been shown to be involved in BL pathogenesis. In BL, TCF3 is constitutively active,and/orexpression of its transcriptional targetsare alteredas a result of BL-associated mutations. Here, we found that BL-related TCF3 mutations affect TCF3 alternative splicing,in part by reducing binding of the splicing regulatorhnRNPH1 to exon 18b. This leads to greater exon 18b inclusion, thereby generating more of the mutated E47 isoform of TCF3...
May 23, 2020: RNA Biology
Rumeng Yang, Zitian Huo, Yaqi Duan, Weilin Tong, Yiyun Zheng, Yinxia Su, Liping Lou, Qian Zhang, Sanpeng Xu, Changqing Peng, Dong Kuang, Guoping Wang
SOX11 is a critical biomarker for mantle cell lymphoma (MCL) diagnosis; however, its role remains unclear in MCL. Here, clinical-pathological analysis showed Ki67 index was negatively relevant to SOX11 expression only in CD43 positive cases. Coexpression of SOX11/CD43 indicated longer overall survival. In vitro , knockout/overexpression of SOX11 or CD43 promoted/inhibited cell proliferation respectively. CD43 overexpression reversed tumor proliferation induced by SOX11 knockdown. Furthermore, overexpressing/silencing the SOX11/CD43 gene affects phosphorylation of p38-MAPK while p38 inhibitor reversed proliferation induced by si-SOX11 or si-CD43, respectively...
May 23, 2020: Leukemia & Lymphoma
Hideki Goto, Shinichi Makita, Koji Kato, Kota Tokushige, Taizo Fujita, Koichi Akashi, Koji Izutsu, Takanori Teshima
BACKGROUND: Tisagenlecleucel demonstrated a high rate of durable response in adult patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL) in the pivotal global phase 2 JULIET study. Here, we report the efficacy and safety of tisagenlecleucel in the Japanese subgroup. METHODS: JULIET (NCT02445248) is a single-arm, open-label, multicenter, phase 2 study involving adult patients with r/r DLBCL who either relapsed after or were ineligible for autologous stem cell transplant...
May 24, 2020: International Journal of Clinical Oncology
Zenggang Pan, Mina L Xu
While the lung is frequently involved by systemic lymphoma, primary pulmonary lymphoma accounts for less than 1% of all extranodal ymphomas. In particular, T-cell lymphoma is very rare in the lung, as a primary or secondary lesion. Patients with pulmonary T-cell lymphoma usually present with cough, dyspnea, pain, fever, recurrent infections, and hemoptysis. Typical radiologic features include pulmonary nodules, consolidation, solid pulmonary opacities, cystic changes, hilar adenopathy, and pleural effusions...
May 16, 2020: Seminars in Diagnostic Pathology
Zohreh Zare, Sam Zarbakhsh, Mohsen Tehrani, Moslem Mohammadi
To determine the possible role of apoptosis in the development of paraoxon-induced brain damage, we evaluated expression of apoptosis-related proteins, the extent of neuronal damage, and activation of astrocytes in rat hippocampus. Adult male Wistar rats were intraperitoneally injected with one of three doses of paraoxon (0.3, 0.7, or 1 mg/kg) or corn oil (vehicle). After 14 or 28 days, expression of apoptosis-related proteins, including B-cell leukemia/lymphoma-2 (Bcl-2), Bcl-2 associated X protein (Bax), and caspase-3, as well as the number of neurons and glial fibrillary acidic protein (GFAP) positive cells in hippocampus were examined by western blot, cresyl blue staining, and immunohistochemistry, respectively...
June 2020: Pesticide Biochemistry and Physiology
André-Dante Durham, Alban Lovis, Julien Simons, Olivier Long, Flore Buela, Adam Ogna, Raphaël Jumeau, Anne Cairoli, Susana Rocha Do Carmo Leal, Michele Zeverino, David Patin, Véronique Vallet, Raphaël Moeckli, Jean Bourhis, Mahmut Ozsahin
BACKGROUND AND PURPOSE: Early-stage Hodgkin lymphoma (HL) is a highly curable disease but the treatment can induce late complications many years later. Irradiation of the healthy heart is inevitable during radiation treatment of mediastinal sites. We developed a novel method to induce a prolonged apnea-like state that can help decrease the dose to organs at risk during radiation therapy. We present the results of the first 8 HL patients treated routinely with percussion assisted radiation therapy (PART) in our clinic...
May 21, 2020: Radiotherapy and Oncology
Erin Mulvey, Jia Ruan
Peripheral T cell lymphomas are heterogeneous diseases which remain treatment challenges. Recent advances in molecular and genomic profiling have provided unprecedented insight into disease pathogenesis driven by distinct cells of origins and molecular pathways. The discovery and clinical application of molecular biomarkers in PTCL subtypes has the potential to transform personalized care for patients with PTCL in diagnosis, prognosis, and therapy. Targeting CD30+ PTCL with the antibody-drug conjugate brentuximab vedotin in the relapsed setting and in combination with chemotherapy in the frontline setting has improved patient survivals...
May 24, 2020: Journal of Hematology & Oncology
D W Pang, F L Chen, W Y Li
No abstract text is available yet for this article.
April 14, 2020: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
D J Li, Y Z Kan, Z G Xu, H Kang, X M Dong, L F Kong
No abstract text is available yet for this article.
April 14, 2020: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
J Y Gu, Y Zhang, X Wang, J J Xiang, S Deng, D J Wu, J F Chen, L H Yu, Y Zhou, Y K Wang, J P Shen
No abstract text is available yet for this article.
April 14, 2020: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
Miguel García-Domínguez, Estivaliz Arizel De la O-Espinoza, Mario Cruz-Muñoz
BACKGROUND: The Wiskott-Aldrich syndrome is a combined immunodeficiency associated with a syndrome linked to the X chromosome, which is characterized by eczema, recurrent infections, and thrombocytopenia. Other manifestations include autoimmune disorders such as hemolytic anemia or thrombocytopenic purpura mediated by the immune system, increased susceptibility to malignant tumors, including lymphoma or leukemia. CLINICAL CASE: A 7-year-old male patient with a diagnosis of Wiskott-Aldrich syndrome who was treated with intravenous gamma globulin, antimicrobial prophylaxis with trimethoprim/sulfamethoxazole, and fluconazole, as well as with prednisone and cyclosporine due to hemolytic anemia and uveitis...
January 2020: Revista Alergia Mexico: Organo Oficial de la Sociedad Mexicana de Alergia e Inmunología, A.C
Ma Li, Hou Yali, Liu Guijun, Fang Dong
Extranodal natural killer/T cell lymphoma, nasal type (ENKL) is a rare and aggressive tumor that can mimic inflammatory conditions and other tumors, and present a diagnostic challenge. We report a 57-year-old Chinese man previously misdiagnosed with rhinoscleroma. The patient had undergone multiple biopsies when the histopathological diagnosis of ENKL was made. Because the diagnosis may be obscured by extensive necrosis, multiple biopsies are necessary to make a certain diagnosis. According to the diagnosis process of this patient, the need to consider a neoplastic cause should be highlighted when faced with an aggressive nasal disease not responsive to maximal treatment...
May 21, 2020: Journal of Stomatology, Oral and Maxillofacial Surgery
Goshi Fujimoto
INTRODUCTION: Cholecystoenteric fistula (CEF) is rare in biliary tract surgery, and cholecystogastric fistula (CGF) is the rarest form of CEF. Although open cholecystectomy with the closure of the fistula is the gold standard treatment for nonobstructing biliary-enteric fistulas, the optimal treatment for CGF has not been established. Laparoscopic and endoscopic cooperative surgery (LECS), a minimally invasive surgery for gastric submucosal tumors, reportedly helps achieve favorable postoperative outcomes...
May 15, 2020: International Journal of Surgery Case Reports
Christopher M Wright, Michael J LaRiviere, Jonathan A Baron, Chibueze Uche, Ying Xiao, W Tristram Arscott, Emily J Anstadt, Andrew R Barsky, David Miller, Meredith I LaRose, Daniel J Landsburg, Jakub Svoboda, Sunita D Nasta, James N Gerson, Stefan K Barta, Elise A Chong, Stephen J Schuster, Ima Paydar, Amit Maity, John P Plastaras
PURPOSE: CD19-targeting chimeric antigen receptor T-cell (CART) therapy has emerged as a promising treatment for relapsed/refractory aggressive B-cell lymphoma (r/rABL), culminating in two FDA-approved therapies, tisagenlecleucel (tisa-cel) and axicabtagene ciloleucel (axi-cel). Following leukapheresis and in preparation for CART infusion, contemporary bridging and lymphodepletion regimens rely mostly on cytotoxic chemotherapy. Here, in a cohort of patients treated with commercial tisa-cel and axi-cel, we show that bridging radiation therapy (bridging-RT) may offer a supplemental approach...
May 21, 2020: International Journal of Radiation Oncology, Biology, Physics
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"